
LIANY
Healthcare · Biotechnology · $5.3M market cap
$0.0488+0.00 (+6.1%)Nov 13, 12:31 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 23, 2026 | Time not confirmed | — | 0.00 | — |
| Nov 28, 2025 | Time not confirmed | — | 0.00 | — |
| Aug 29, 2025 | Time not confirmed | — | 0.00 | — |
| May 30, 2025 | Time not confirmed | — | 0.00 | — |
| Mar 24, 2025 | Time not confirmed | -0.09 | -0.22 | -144.4% |
| Dec 5, 2024 | Time not confirmed | -0.09 | 0.00 | +100.0% |
| Aug 8, 2024 | Time not confirmed | -0.09 | 0.00 | +100.0% |
| May 9, 2024 | Time not confirmed | -0.09 | 0.00 | +100.0% |
| Mar 25, 2024 | After the close | -0.19 | 3.55 | +1967.9% |
| Nov 13, 2023 | After the close | -0.33 | -0.22 | +33.3% |
| Aug 14, 2023 | After the close | -0.28 | -0.20 | +28.6% |
| May 11, 2023 | After the close | -0.27 | -0.22 | +18.5% |
| Mar 27, 2023 | Time not confirmed | -0.17 | -0.17 |
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA…
| 0.0% |
| Nov 10, 2022 | After the close | -0.39 | -0.20 | +48.7% |
| Aug 11, 2022 | After the close | -0.27 | -0.39 | -44.4% |
| May 12, 2022 | Time not confirmed | — | -0.26 | — |
| Mar 30, 2022 | After the close | -0.89 | -0.28 | +68.5% |
| Dec 9, 2021 | After the close | -0.71 | -0.63 | +11.3% |